Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NRP1 | O14786 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | F13A1 | P00488 | 1/20 | 0.34 |
| ▸ | TGM1 | P22735 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806465 | 1.00 | NRP1 (0.37) | NRP1MMP2MMP9F13A1TGM1 | |
| SCHEMBL2806461 | 1.00 | NRP1 (0.37) | NRP1MMP2MMP9F13A1TGM1 | |
| SCHEMBL13128313 | 0.92 | L3MBTL1 (0.36) | NRP1MMP2MMP9F13A1TGM1 | |
| SCHEMBL2807798 | 0.85 | ALDH1A1 (0.33) | NRP1 | |
| SCHEMBL2807794 | 0.85 | ALDH1A1 (0.33) | NRP1 | |
| SCHEMBL2807797 | 0.85 | ALDH1A1 (0.33) | NRP1 | |
| SCHEMBL2812800 | 0.79 | MMP2 (0.47) | NRP1MMP2MMP9F13A1TGM1 | |
| SCHEMBL2812796 | 0.79 | MMP2 (0.47) | NRP1MMP2MMP9F13A1TGM1 | |
| SCHEMBL2808808 | 0.78 | ALDH1A1 (0.41) | NRP1MMP2MMP9F13A1TGM1 | |
| SCHEMBL2808807 | 0.78 | ALDH1A1 (0.41) | NRP1MMP2MMP9F13A1TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | NRP1 3527/4885MMP2 161/4885MMP9 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.